Myasthenia gravis supplement inhibitor meets primary endpoint in phase 3 trial
(MedPage Today) – San Francisco – Investigational drug gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR)-positive myasthenia gravis (MG), main-line data from phase III PREVAIL…